GLPwatch

Poly(l-threonine-<i>co</i>-l-threonine Succinate) Thermogels for Sustained Release of Lixisenatide.

Biomacromolecules · 2024

Last updated 2026-05-28

A new gel-like material (PTTs) was developed to slowly release the diabetes drug lixisenatide. When tested, 77% of the lixisenatide dose was released over 14 days, and blood sugar control lasted 7–10 days in diabetic rats. The gel worked by using electrical charge to reduce the initial rapid release of the drug.

AI summary of the abstract below.

JournalBiomacromolecules, 2024
Citations4
Relative citation ratio0.74
NIH percentile41
Molecules lixisenatide
Conditions studied Type 2 Diabetes, Obesity

Abstract

Negatively charged poly(l-Thr--l-Thr succinate) (PTTs) was developed as a new thermogel. Aqueous PTT solutions underwent thermogelation over a concentration range of 6.0-8.3 wt %. Dynamic light scattering, FTIR, H NMR, and COSY spectra revealed the partial strengthening of the β-sheet conformation and the dehydration of PTTs during the transition. Extendin-4 was released from the PTTs thermogel with a large initial burst release, whereas positively charged lixisenatide significantly reduced its initial burst release to 25%, and up to 77% of the dose was released from the gel over 14 days. In vivo study revealed a high plasma concentration of lixisenatide over 5 days and hypoglycemic efficacy was observed for type II diabetic rats over 7-10 days. The biocompatible PTTs were degraded by subcutaneous enzymes. This study thus demonstrates an effective strategy for reducing the initial burst release of protein drugs from thermogels with the introduction of electrostatic interactions between the drug and the thermogel.

Verbatim abstract via PubMed 38949062 ↗

Related research